T J Unger
Overview
Explore the profile of T J Unger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
269
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pearson A, Federico S, Gatz S, Ortiz M, Lesa G, Scobie N, et al.
Eur J Cancer
. 2023 Jul;
190:112950.
PMID: 37441939
DNA damage response inhibitors have a potentially important therapeutic role in paediatric cancers; however, their optimal use, including patient selection and combination strategy, remains unknown. Moreover, there is an imbalance...
2.
Cornell R, Baz R, Richter J, Rossi A, Vogl D, Chen C, et al.
Am J Hematol
. 2021 Nov;
97(2):E54-E58.
PMID: 34817872
No abstract available.
3.
Qasim S, Sierra L, Shuck R, Kurenbekova L, Patel T, Rajapakshe K, et al.
Oncogene
. 2021 Jan;
40(6):1176-1190.
PMID: 33414491
Ewing sarcoma (ES) is the second most common bone tumor in children and young adults. Unfortunately, there have been minimal recent advancements in improving patient outcomes, especially in metastatic and...
4.
Gavriatopoulou M, Chari A, Chen C, Bahlis N, Vogl D, Jakubowiak A, et al.
Leukemia
. 2020 Feb;
34(9):2430-2440.
PMID: 32094461
Selinexor is an oral, small molecule inhibitor of the nuclear export protein exportin 1 with demonstrated activity in hematologic and solid malignancies. Side effects associated with selinexor include nausea, vomiting,...
5.
Vergote I, Lund B, Peen U, Umajuridze Z, Mau-Sorensen M, Kranich A, et al.
Gynecol Oncol
. 2019 Dec;
156(2):308-314.
PMID: 31822399
Background: Selinexor is an oral inhibitor of the nuclear export protein Exportin 1 (XPO1) with demonstrated antitumor activity in solid and hematological malignancies. We evaluated the efficacy and safety of...
6.
Bahlis N, Sutherland H, White D, Sebag M, Lentzsch S, Kotb R, et al.
Blood
. 2018 Oct;
132(24):2546-2554.
PMID: 30352784
Selinexor is an oral inhibitor of the nuclear export protein exportin 1. Preclinical studies demonstrated synergistic antimyeloma activity between selinexor and proteasome inhibitors (PI) through suppression of NF-κB signaling and...
7.
Chen C, Siegel D, Gutierrez M, Jacoby M, Hofmeister C, Gabrail N, et al.
Blood
. 2017 Dec;
131(8):855-863.
PMID: 29203585
Novel therapies are needed for patients with relapsed or refractory multiple myeloma (MM). We conducted a multicenter, phase 1 study in advanced hematological malignancies to assess the safety, efficacy, and...
8.
Machlus K, Wu S, Vijey P, Soussou T, Liu Z, Shacham E, et al.
Blood
. 2017 Jun;
130(9):1132-1143.
PMID: 28630120
Selinexor is the first oral selective inhibitor of nuclear export compound tested for cancer treatment. Selinexor has demonstrated a safety therapy profile with broad antitumor activity against solid and hematological...
9.
Chan J, Unger T, Byrnes J, Rios M
Neuroscience
. 2006 Jul;
142(1):49-58.
PMID: 16844311
Human and animal studies have implicated brain-derived neurotrophic factor (BDNF) in the etiology of psychiatric disorders. It is expressed in limbic regions of the brain associated with the regulation of...